NEULANDLAB

Neuland Laboratories Share Price

 

 

Invest in Neuland Laboratories with 2.67X leverage

Invest with MTF

Performance

  • Low
  • ₹13,105
  • High
  • ₹13,602
  • 52 Week Low
  • ₹10,191
  • 52 Week High
  • ₹19,747
  • Open Price₹13,569
  • Previous Close₹13,570
  • Volume26,161
  • 50 DMA₹15,154.01
  • 100 DMA₹15,165.46
  • 200 DMA₹14,457.62

Investment Returns

  • Over 1 Month -12.16%
  • Over 3 Month -17.63%
  • Over 6 Month -3.99%
  • Over 1 Year -3.86%

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Invest Now

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 70.8
  • PEG Ratio
  • -5
  • Market Cap Cr
  • 17,001
  • P/B Ratio
  • 10.5
  • Average True Range
  • 527.48
  • EPS
  • 152.61
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -541.56
  • RSI
  • 30.48
  • MFI
  • 18.88

Neuland Laboratories Financials

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹13,251.00
-319 (-2.35%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹14,392.89
  • 50 Day
  • ₹15,154.01
  • 100 Day
  • ₹15,165.46
  • 200 Day
  • ₹14,457.62

Resistance and Support

13319.33 Pivot Speed
  • R3 14,030.67
  • R2 13,816.33
  • R1 13,533.67
  • S1 13,036.67
  • S2 12,822.33
  • S3 12,539.67

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Neuland Laboratories is a leading pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. It serves global pharmaceutical companies with high-quality APIs for critical therapeutic areas, including cardiovascular and central nervous system.

Neuland Laboratories has an operating revenue of Rs. 1,533.42 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 23% is great, ROE of 17% is exceptional. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 63 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 69 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-09 Quarterly Results
2025-11-07 Quarterly Results
2025-07-31 Quarterly Results
2025-05-15 Audited Results & Final Dividend
2025-02-10 Quarterly Results
Date Purpose Remarks
2025-07-18 FINAL Rs.12.00 per share(120%)Final Dividend
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend
View Neuland Laboratories Dividend History Arrow

Neuland Laboratories F&O

Neuland Laboratories Shareholding Pattern

32.63%
10.39%
1.17%
20.9%
0.01%
24.31%
10.59%

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹13,251 As on 26 January, 2026 | 06:48

The Market Cap of Neuland Laboratories is ₹17000.9 Cr As on 26 January, 2026 | 06:48

The P/E ratio of Neuland Laboratories is 70.8 As on 26 January, 2026 | 06:48

The PB ratio of Neuland Laboratories is 10.5 As on 26 January, 2026 | 06:48

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23